Clinical Trials Logo

Ocular Hypertension clinical trials

View clinical trials related to Ocular Hypertension.

Filter by:

NCT ID: NCT02108288 Completed - Glaucoma Clinical Trials

Pharmacokinetic Study of OPC-1085EL Ophthalmic Solution in Healthy Male Adult Volunteers

Start date: April 2014
Phase: Phase 1
Study type: Interventional

OPC-1085EL ophthalmic solution, carteolol long-acting ophthalmic solution or latanoprost ophthalmic solution are administered once daily for 7 days and the effect on the blood concentration of carteolol and latanoprost in OPC-1085EL ophthalmic solution by formulating the combination drug will be determined.

NCT ID: NCT02105285 Completed - Glaucoma Clinical Trials

Efficacy and Safety Study of OPC-1085EL Ophthalmic Solution in Subjects With Glaucoma or Ocular Hypertension

Start date: April 2014
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine the efficacy and safety of OPC-1085EL ophthalmic solution in comparison with carteolol long-acting ophthalmic solution in subjects who are insufficiently responsive to carteolol long-acting ophthalmic solution.

NCT ID: NCT02105272 Completed - Glaucoma Clinical Trials

Efficacy and Safety Study of OPC-1085EL Ophthalmic Solution in Subjects With Glaucoma or Ocular Hypertension

Start date: April 2014
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine the efficacy and safety of OPC-1085EL ophthalmic solution in comparison with latanoprost ophthalmic solution in subjects who are insufficiently responsive to latanoprost ophthalmic solution.

NCT ID: NCT02102750 Completed - Glaucoma Clinical Trials

A Study to Evaluate Pharmacokinetics of Tafluprost Ophthalmic Solution (0.0015%) in Pediatric Patients With Glaucoma or Ocular Hypertension

Start date: June 2014
Phase: Phase 1
Study type: Interventional

The purpose of the study is to examine how preservative free tafluprost ophthalmic solution (0.0015%) is distributed in blood circulation after ocular administration in children who have glaucoma or elevated intraocular pressure. Tolerance to the drug and safety in general will also be assessed.

NCT ID: NCT02097719 Completed - Glaucoma Clinical Trials

Efficacy and Safety Study of Bimatoprost 0.01% Alone Compared With Travoprost 0.004% and Timolol 0.5% in Subjects With Glaucoma or Ocular Hypertension

Start date: May 2014
Phase: Phase 4
Study type: Interventional

This efficacy and safety study will evaluate LUMIGAN® .01 (bimatoprost 0.01%) alone compared to TRAVATAN Z® (travoprost 0.004%) and TIMOLOL GFS, 0.5% (timolol 0.5% ophthalmic gel forming solution) in patients who require IOP lowering therapy.

NCT ID: NCT02083289 Completed - Ocular Hypertension Clinical Trials

A 28 Day Study of ONO-9054 Ophthalmic Solution in Subjects With Ocular Hypertension (OHT) or Open-angle Glaucoma (OAG)

Start date: May 2014
Phase: Phase 2
Study type: Interventional

The primary objectives of this study are to compare the safety, tolerability, and mean change from baseline in diurnal intraocular pressure (IOP) of ONO-9054 30 µg/mL (0.003%) to latanoprost 0.005% following ocular instillation once every evening for 28 days.

NCT ID: NCT02061683 Completed - Ocular Hypertension Clinical Trials

A Study of Bimatoprost in the Treatment of Primary Open Angle Glaucoma and Ocular Hypertension

LOTUS
Start date: April 19, 2010
Phase: Phase 4
Study type: Interventional

This is a study of bimatoprost as initial, replacement, or adjunctive intraocular pressure (IOP)-lowering therapy in patients with primary open angle glaucoma and ocular hypertension.

NCT ID: NCT02059278 Completed - Ocular Hypertension Clinical Trials

Safety and Efficacy of T-2345 Compared to Xalatan in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension

Start date: January 2014
Phase: Phase 3
Study type: Interventional

This is a Phase 3 study to evaluate the safety and efficacy of T-2345 dosed to one of both eyes once daily for 84 days compared to Xalatan dosed to one of both eyes once daily for 84 days in patients with elevated eye pressure.

NCT ID: NCT02057575 Completed - Ocular Hypertension Clinical Trials

Study Assessing Safety and Efficacy of PG324 Ophthalmic Solution in Patients With Elevated Intraocular Pressure

Start date: January 2014
Phase: Phase 2
Study type: Interventional

To evaluate the ocular hypotensive efficacy of PG324 ophthalmic solution relative to its individual components in patients with open angle glaucoma or ocular hypertension.

NCT ID: NCT02020512 Completed - Ocular Hypertension Clinical Trials

A Study of 0.03% Bimatoprost in the Treatment of Primary Open Angle Glaucoma and Ocular Hypertension

LOTUSDI
Start date: July 2011
Phase: Phase 4
Study type: Interventional

This study will evaluate 0.03% bimatoprost in the treatment of primary open angle glaucoma and ocular hypertension.